Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00407121

Enrollment

Registered

2006-12-04

Start date

2006-12-31

Completion date

2006-12-31

Last updated

2024-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multifocal Choroiditis, Serpiginous Choroiditis, Vogt Koyanagi Harada Disease

Keywords

Neovascular Membrane, Uveitis, Bevacizumab

Brief summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Interventions

DRUGBevacizumab

PROCEDUREIntravitreal Injection of Bevacizumab

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Clinical Diagnose * Patient Consent * Chronic stage of inflammation

Exclusion criteria

* only eye * age lower than 30 yo. * Systemic condition

Design outcomes

Primary

Measure	Time frame
Best corrected visual acuity	—
Retinal thickness by OCT	—
Leakage in Fluorescein angiogram	—

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026